» Articles » PMID: 37143011

Cost-effectiveness Analysis of Sarcopenia Management Interventions in Iran

Overview
Publisher Biomed Central
Specialty Public Health
Date 2023 May 4
PMID 37143011
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Identification the optimal management intervention of sarcopenia is a concern of health systems. We aimed to analyze the cost-effectiveness of sarcopenia management strategies in Iran.

Methods: We constructed a lifetime Markov model based on natural history. The strategies comparedincluded exercise training, nutritional supplements, whole body vibration (WBV), and various exercise interventions and nutritional supplement combinations. A total of 7 strategies was evaluated in addition to the non-intervention strategy. Parameter values were extracted from primary data and the literature, and the costs and Quality-adjusted life years (QALYs) were calculated for each strategy. Deterministic and probabilistic sensitivity analysis, including the expected value of perfect information (EVPI), was also performed to determine the robustness of the model. Analyses were performed using the 2020 version of TreeAge Pro software.

Results: All seven strategies increased lifetime effectiveness (QALYs). The protein and Vitamin D (P + D) strategy had the highest effectiveness values among all strategies. After removing the dominated strategies, the estimated ICER for the P + D compared to Vitamin D alone (D) strategy was calculated as $131,229. Considering the cost-effectiveness threshold ($25,249), base-case results indicated that the D strategy was the most cost-effective strategy in this evaluation. Sensitivity analysis of model parameters also demonstrated the robustness of results. Also, EVPI was estimated at $273.

Conclusions: Study results, as the first economic evaluation of sarcopenia management interventions, showed that despite the higher effectiveness of D + P, the D strategy was the most cost-effective. Completing clinical evidence of various intervention options can lead to more accurate results in the future.

Citing Articles

The effect of Sarcomeal® oral supplementation plus vitamin D3 on muscle parameters and metabolic factors in diabetic sarcopenia patients: study protocol of a randomized controlled clinical trial.

Abdi Dezfouli R, Zargar Balajam N, Shirazi S, Heshmat R, Shafiee G Trials. 2024; 25(1):848.

PMID: 39716287 PMC: 11667863. DOI: 10.1186/s13063-024-08700-x.


Economic burden of sarcopenia-related disability in the elderly population: a study in Iran.

Darvishi A, Nikkhah A, Shafiee G, Daroudi R, Heshmat R BMC Res Notes. 2024; 17(1):319.

PMID: 39449070 PMC: 11520130. DOI: 10.1186/s13104-024-06975-6.


Skeletal Muscle Area on CT: Determination of an Optimal Height Scaling Power and Testing for Mortality Risk Prediction.

Blankemeier L, Yao L, Long J, Reis E, Lenchik L, Chaudhari A AJR Am J Roentgenol. 2023; 222(1):e2329889.

PMID: 37877596 PMC: 11890211. DOI: 10.2214/AJR.23.29889.

References
1.
Johnell O, Kanis J, Oden A, Sernbo I, Redlund-Johnell I, Petterson C . Mortality after osteoporotic fractures. Osteoporos Int. 2003; 15(1):38-42. DOI: 10.1007/s00198-003-1490-4. View

2.
Goates S, Du K, Arensberg M, Gaillard T, Guralnik J, Pereira S . Economic Impact of Hospitalizations in US Adults with Sarcopenia. J Frailty Aging. 2019; 8(2):93-99. DOI: 10.14283/jfa.2019.10. View

3.
Darvishi A, Hemami M, Shafiee G, Daroudi R, Mohseni M, Shekarabi F . Sarcopenia screening strategies in older people: a cost effectiveness analysis in Iran. BMC Public Health. 2021; 21(1):926. PMC: 8127291. DOI: 10.1186/s12889-021-10511-7. View

4.
Tsekoura M, Kastrinis A, Katsoulaki M, Billis E, Gliatis J . Sarcopenia and Its Impact on Quality of Life. Adv Exp Med Biol. 2017; 987:213-218. DOI: 10.1007/978-3-319-57379-3_19. View

5.
Sakuma K, Yamaguchi A . Recent advances in pharmacological, hormonal, and nutritional intervention for sarcopenia. Pflugers Arch. 2017; 470(3):449-460. DOI: 10.1007/s00424-017-2077-9. View